Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE changes Xolair recommendation

  • Comment

NICE has ruled that Xolair should not be provided on the NHS as standard asthma treatment.

At the moment many asthma sufferers are given Xolair, which is also known as omalizumab, to help them control the condition in addition to other medication. But after studying whether the treatment offers value for money, the health watchdog has recommended that it should not be given to those with severe allergic asthma.

It has however said patients who have already been prescribed it can carry on taking the drug until it is considered the right time to stop by a medical professional.

NICE chief executive Sir Andrew Dillon said the organisation understood that serious and long-lasting allergic asthma had a negative impact on the lives of sufferers and that for many people omalizumab was an “effective therapy”.

Olympic swimmer Jo Jackson has credited the drug with helping her continue her sporting career.

The athlete, who picked up a bronze medal in Beijing four years ago, suffered serious asthma attacks while training until she started taking Xolair.

Jo, who swam the women’s 400m freestyle at the London 2012 Games, said that without the drug she may have had to stop competing.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs